BlossomHill Therapeutics, Inc.

Recent biopharmaceutical venture capital financings reflect a worldly investment view, even at the $100m-plus mega-round level where the largest investments tend to be more frequent in the US. The six

FogPharma ended 2022 with a big cash haul – $178m from a series D venture capital round – and in 2023 achieved a couple of big milestones that helped the company raise its next big financing this yea